ArticleNature communications2025
Strong and early monkeypox virus-specific immunity associated with mild disease after intradermal clade-IIb-infection in CAST/EiJ-mice.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Comparative pathogenicity study of monkeypox virus Clade Ib and Clade IIb in a rabbit model.Virulence · 2026Article
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Molecular cloning of a monkeypox virus clade IIb genome and construction of an attenuated mutant for basic and translational research.Emerging microbes & infections · 2026Article
- Mpox animal models: a comprehensive evaluation of susceptible species for pathogenesis studies and drug discovery.Emerging microbes & infections · 2026Review
- A single-dose inhalable rAAV-vectored vaccine against mpox virus.Cell reports. Medicine · 2026Article
- Antifolate agent aminopterin demonstrates potent anti-monkeypox virus activityMicrobiology spectrum · 2026Article
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- CAST/EiJ and NOG mice as lethal animal models for a 2022 human isolate of monkeypox virus Clade IIb.Scientific reports · 2026Article
- Enhanced virulence of mpox virus clade Ib over clade IIb in the CAST/EiJ mouse model.Communications biology · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- From skin lesions to multi-organ involvement: Organ tropism and pathogenesis of mpox virus.iScience · 2025Review
- Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice.Nature communications · 2025Article
- Review
- Mpox: disease manifestations and therapeutic development.Journal of virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Monkeypox virus (MPXV) is a zoonotic poxvirus long endemic in West and Central Africa. Outbreaks, first the global spread of clade II outside Africa in 2022, and since 2023 the accelerating spread of clade I in central Africa, point to MPXV adaptations that pose the risk of it becoming more transmissible in humans. Animal models mimicking the clinical disease outcome in humans are important to better understand pathogenesis, host tropism, and the contribution of genetic mutations. Here, we demonstrate that MPXV infection via tail scarification in CAST/EiJ mice is an appropriate animal model to mimic human mpox. In our study, disease outcome is milder in clade IIb than clade IIa-infected mice, which is associated with enhanced immunogenicity early during infection. This suggests that clade IIb more efficiently activates host immune responses, highlighting how this animal model could facilitate studying new MPXV variants to help develop efficient antivirals and preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.